ABSTRACT
Objective To investigate the proliferation and invasion of human pancreatic cancer cells after Stat1 gene silenced or enhanced and to explore the possible mechanisms.Methods BxPC-3 cells were divided to three groups: Stat1 group transfected with specific Stat1 plasmid, Si Stat1 group transfected with specific Stat1 small interfering RNA (siRNA), and control group.Western blot was used to detect the expression of Stat1, VEGF, MMP-2 and MMP-9 in BxPC-3 cells.MTT method was used to detect the proliferation of BxPC-3 cells.Transwell was used to detect the invasion of BxPC-3 cells.Results The proliferation and invasion were significantly enhanced in pancreatic cancer cells after Stat1 gene silenced, and the expression of VEGF, MMP-2 and MMP-9 was increased.The proliferation and invasion were significantly decreased in pancreatic cancer cells after Stat1 gene enhanced.Conclusions Stat1 inhibits the proliferation and invasion of pancreatic cancer cells.VEGF,MMP-2 and MMP-9 possibly play a role in this process.
ABSTRACT
Objective To investigate whether emodin enhances chemosensitivity of pancreatic cancer cells and the mechanism. Methods Normal human skin fibroblasts and pancreatic BXPC-3 cells were divided into control group, cisplatin (5 mg/L) treatment group, gemcitabine (0.5 μmol/L) treatment group, emodin (50 μmol/L)+ cisplatin (5 mg/L) co-treatment group and emodin (50 μmol/L) + gemcitabine (0.5 μmol/L) co-treatmentgroup. The cell viability was detected by MTT assay, the cell apoptosis rate by flow cytometry, the expression of the multidrug resistance-associated protein 1 ( MRP1 ), MRP2, breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) mRNA in different cell lines was determined by reverse transcription polymerase chain reaction.All data were analyzed using the t test. Results The cell viability and apoptosis rate of pancreatic BXPC-3 cells after treatment were 62.44% ± 3.42% and 27. 10% ± 4.24% in the cisplatin treatment group, and they were 30.53% ±0.05% and 66.33% ±9.37% in the emodin + cisplatin co-treatment group. There were significant differences in cell viability and apoptosis rate between the two groups (t = 13.20, 5. 35, P < 0.05 ). The cell viability and apoptosis rate of pancreatic BXPC-3 cells after treatment were 79.82% ±2.83% and 13.48% ± 1.65%in the gemcitabine treatment group, and they were 45.65% ± 2.46% and 62.74% ± 10. 18% in the emodin +gemcitabine co-treatment group. There were significant differences in cell viability and apoptosis rate between the two groups (t = 12.89, 8.28, P < 0. 05 ). There was no significant difference in the viability of normal human skin fibroblasts between the cisplatin treatment group and the emodin + cisplatin co-treatment group, and also between the gemcitabine treatment group and the emodin + gemcitabine co-treatment group (t = 2. 08, 0. 64, P >0.05 ). Expression of MRP1 mRNA was detected in pancreatic BXPC-3 cells, whereas the expression of MRP2,BCRP and P-gp mRNA was undetectable. The expression of MRP1 mRNA in pancreatic BXPC-3 cells was significantly down-regulated in the cisplatin treatment group, and cisplatin + emodin co-treatment had an additive effect on down-regulating the expression of MRP1 mRNA. Conclusion Emodin may enhance chemosensitivity of pancreatic cancer cells to cisplatin by down-regulating the expression of MRP1 mRNA.